17 March 2023Multispectral imaging quantifies available immune-inhibitory receptor concentrations for therapeutic binding of anti-PD-1 checkpoint inhibitors
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Immune checkpoint inhibitors (ICIs) are among the most effective classes of cancer immunotherapies yet only a small minority of patients derive clinical benefit. We are investigating the use of multi-spectral paired-agent imaging (mPAI) to quantify available PD-1 and PD-L1 receptor concentrations for the therapeutic binding of anti-PD-1 checkpoint inhibitors.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Divya Ravi, Abdibaset A. Bare, Emma M. Cammack, Veronica C. Torres, Kimberley S Samkoe, "Multispectral imaging quantifies available immune-inhibitory receptor concentrations for therapeutic binding of anti-PD-1 checkpoint inhibitors," Proc. SPIE 12357, Visualizing and Quantifying Drug Distribution in Tissue VII, 123570H (17 March 2023); https://doi.org/10.1117/12.2650637